In 2023, Astellas Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Astellas Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Astellas Pharma amounted to 122,250 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Astellas Pharma increased by 3.92%, suggesting that the company faced challenges in reducing its emissions from its core operations.
In 2023, the total Scope 1 emissions of Astellas Pharma were 59,203 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Since 2019, Astellas Pharma's Scope 1 emissions have decreased by 16.5%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Astellas Pharma's Scope 1 emissions decreased by 3.22%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
In 2023, Astellas Pharma reported Scope 2 greenhouse gas (GHG) emissions of 63,047 tCOâ‚‚e using the market-based method.
Since 2019, Astellas Pharma's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 33.8%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Astellas Pharma's Scope 2 emissions (Market-Based) rose by 11.64% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
In 2023, Astellas Pharma reported its Scope 2 emissions using the market-based method.